Lewis Michelle Renee sold $600K of PACS

Lewis Michelle Renee (Chief Accounting Officer) sold 15,000 shares of PACS Group, Inc. (PACS) at $40.01 ($0.60M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lewis Michelle Renee
Published Jun 26, 2026, 10:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 10:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PACS
Neutral
medium confidence
Mentioned
$PACS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PACSNeutralLow
01

Why it matters

The CFO’s open-market sale under a 10b5-1 plan is primarily a compliance disclosure; it may slightly affect sentiment but does not introduce new business information.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a fundamental repricing.

03

What to watch

The article provides only the sale size and plan flag; it does not state total insider holdings changes beyond the post-transaction share count, nor any concurrent buys/sales by other insiders.

Relevance 4/10Novelty 4/10Timing: Filed 2026-06-26 after-hours; transaction dated 2026-06-25.

Background

The article is a SEC Form 4 insider transaction disclosure for PACS Group, Inc.

Company-level read

Ticker impact

$PACSNeutralMedium confidence
Context

PACS Group CFO Lewis Michelle Renee sold $600,178 of PACS shares via an open-market sale under a 10b5-1 plan on 2026-06-25.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any impact would be short-lived sentiment noise.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan, which generally reduces interpretive weight versus discretionary selling.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with management’s private view of valuation or liquidity needs, potentially pressuring sentiment.

Key entities

  • PACS Group, Inc.

    Company whose insider transaction was disclosed on SEC Form 4.

  • Lewis Michelle Renee

    Chief Accounting Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PACSMedAI 8/10

What PACS Group (PACS) Said on Its Q3 Earnings Call

PACS Group reported 196 mature, 90 ramping, and 35 new skilled nursing facilities with occupancy ranging from 76.2% to 93.1%. The company acquired 32 Florida and 10 Texas skilled nursing operations post-quarter. PACS raised its 2026 revenue outlook to $5.95B-$6.05B and adjusted EBITDA to $685M-$695M, citing strength in existing operations and new acquisitions. Operating cash flow was $583.1M for the first nine months of 2026, with $707.4M in available liquidity.

$PACSHighAI 8/10

PACS Group Inc (PACS) (Q3 2026) Earnings Call Highlights: Revenue Tops

PACS Group Inc (NYSE:PACS) reported Q3 2026 revenue growth of 6.4%, with adjusted EBITDA up 33.6% to $175.7M. The company raised full-year guidance, citing strong occupancy and skilled mix improvements. PACS also highlighted a robust acquisition pipeline and integration plans for 31 Eduro facilities. Challenges include lower metrics at newly acquired facilities and ongoing government investigations.

$PACSHigh

Why is PACS stock surging today?

PACS Group Inc (PACS) stock rose 6.0% in after-hours trading after beating Q3 2026 earnings and revenue estimates. The company also raised its full-year 2026 Adjusted EBITDA and revenue guidance. Analysts maintain a 'Moderate Buy' rating with an average price target of $58.80. The surge was driven by company-specific news.